The Bellmunt Risk Score (BRS) has been validated as a reliable prognostic tool for patients with metastatic castration-resistant prostate cancer (mCRPC).
The BRS, which ranges from 0 to 3, assigns one point each for poor performance status, low hemoglobin, and liver metastases. In a study of 1,756 men, higher scores correlated strongly with shorter survival.
In first-line treatment, median overall survival dropped from 42.2 months (BRS 0) to 9.1 months (BRS 3). In post-docetaxel settings, survival fell from 23.0 to 3.2 months across the same range.
The BRS remained an independent predictor in all models, supporting its use in clinical decision-making and shared patient discussions.